Disease-modifying pathways in neurodegeneration

Steven Finkbeiner, Ana Maria Cuervo, Richard I. Morimoto, Paul J. Muchowski

Research output: Contribution to journalArticle

45 Citations (Scopus)

Abstract

The identification and characterization of putative disease-modifying pathways in neurodegenerative disorders has enormous potential for discovery of novel therapeutic agents that target these pathways. In studies of these putative pathways, it is critical to rigorously evaluate causality to the disease process. Findings in model organisms require validation in more physiologically relevant models but have the benefit of identifying targets amenable to modulation by small molecule therapeutics, possibly including drugs already in clinical use. Although many disease-modifying pathways have been reported, few have been validated in vivo in animal models of disease. Nonetheless, given the powerful genetic tools currently available, including a growing list of mouse mutants, the future looks promising and one can expect to see the number of clinical trials based on interventions that target disease-modifying pathways to continue growing.

Original languageEnglish (US)
Pages (from-to)10349-10357
Number of pages9
JournalJournal of Neuroscience
Volume26
Issue number41
DOIs
StatePublished - Oct 11 2006

Fingerprint

Animal Disease Models
Causality
Neurodegenerative Diseases
Clinical Trials
Therapeutics
Pharmaceutical Preparations

ASJC Scopus subject areas

  • Neuroscience(all)

Cite this

Disease-modifying pathways in neurodegeneration. / Finkbeiner, Steven; Cuervo, Ana Maria; Morimoto, Richard I.; Muchowski, Paul J.

In: Journal of Neuroscience, Vol. 26, No. 41, 11.10.2006, p. 10349-10357.

Research output: Contribution to journalArticle

Finkbeiner, S, Cuervo, AM, Morimoto, RI & Muchowski, PJ 2006, 'Disease-modifying pathways in neurodegeneration', Journal of Neuroscience, vol. 26, no. 41, pp. 10349-10357. https://doi.org/10.1523/JNEUROSCI.3829-06.2006
Finkbeiner, Steven ; Cuervo, Ana Maria ; Morimoto, Richard I. ; Muchowski, Paul J. / Disease-modifying pathways in neurodegeneration. In: Journal of Neuroscience. 2006 ; Vol. 26, No. 41. pp. 10349-10357.
@article{068cf3fb2de74e2595e678d0c52752b6,
title = "Disease-modifying pathways in neurodegeneration",
abstract = "The identification and characterization of putative disease-modifying pathways in neurodegenerative disorders has enormous potential for discovery of novel therapeutic agents that target these pathways. In studies of these putative pathways, it is critical to rigorously evaluate causality to the disease process. Findings in model organisms require validation in more physiologically relevant models but have the benefit of identifying targets amenable to modulation by small molecule therapeutics, possibly including drugs already in clinical use. Although many disease-modifying pathways have been reported, few have been validated in vivo in animal models of disease. Nonetheless, given the powerful genetic tools currently available, including a growing list of mouse mutants, the future looks promising and one can expect to see the number of clinical trials based on interventions that target disease-modifying pathways to continue growing.",
author = "Steven Finkbeiner and Cuervo, {Ana Maria} and Morimoto, {Richard I.} and Muchowski, {Paul J.}",
year = "2006",
month = "10",
day = "11",
doi = "10.1523/JNEUROSCI.3829-06.2006",
language = "English (US)",
volume = "26",
pages = "10349--10357",
journal = "Journal of Neuroscience",
issn = "0270-6474",
publisher = "Society for Neuroscience",
number = "41",

}

TY - JOUR

T1 - Disease-modifying pathways in neurodegeneration

AU - Finkbeiner, Steven

AU - Cuervo, Ana Maria

AU - Morimoto, Richard I.

AU - Muchowski, Paul J.

PY - 2006/10/11

Y1 - 2006/10/11

N2 - The identification and characterization of putative disease-modifying pathways in neurodegenerative disorders has enormous potential for discovery of novel therapeutic agents that target these pathways. In studies of these putative pathways, it is critical to rigorously evaluate causality to the disease process. Findings in model organisms require validation in more physiologically relevant models but have the benefit of identifying targets amenable to modulation by small molecule therapeutics, possibly including drugs already in clinical use. Although many disease-modifying pathways have been reported, few have been validated in vivo in animal models of disease. Nonetheless, given the powerful genetic tools currently available, including a growing list of mouse mutants, the future looks promising and one can expect to see the number of clinical trials based on interventions that target disease-modifying pathways to continue growing.

AB - The identification and characterization of putative disease-modifying pathways in neurodegenerative disorders has enormous potential for discovery of novel therapeutic agents that target these pathways. In studies of these putative pathways, it is critical to rigorously evaluate causality to the disease process. Findings in model organisms require validation in more physiologically relevant models but have the benefit of identifying targets amenable to modulation by small molecule therapeutics, possibly including drugs already in clinical use. Although many disease-modifying pathways have been reported, few have been validated in vivo in animal models of disease. Nonetheless, given the powerful genetic tools currently available, including a growing list of mouse mutants, the future looks promising and one can expect to see the number of clinical trials based on interventions that target disease-modifying pathways to continue growing.

UR - http://www.scopus.com/inward/record.url?scp=33749844689&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=33749844689&partnerID=8YFLogxK

U2 - 10.1523/JNEUROSCI.3829-06.2006

DO - 10.1523/JNEUROSCI.3829-06.2006

M3 - Article

VL - 26

SP - 10349

EP - 10357

JO - Journal of Neuroscience

JF - Journal of Neuroscience

SN - 0270-6474

IS - 41

ER -